Reuters: Regulatory News: UPDATE 1- Achillion's hepatitis C drug gets FDA fast track

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UPDATE 1- Achillion's hepatitis C drug gets FDA fast track May 15th 2012, 11:45 Tue May 15, 2012 7:45am EDT May 15 (Reuters) - The U.S. Food and Drug Administration granted a fast track designation to Achillion Pharmaceuticals Inc's experimental hepatitis C drug ACH-3102, currently in an early-stage trial. The fast-track status is designed to expedite the regulatory review of drugs that aim to treat serious diseases and fill unmet medical needs. The New Haven, Connecticut-based company got a fast track designation in January for another of its experimental hepatitis C (HCV) drug ACH-1625, which was in a mid-stage trial. The hepatitis C virus infects the liver and is the most common cause of viral hepatitis, an inflammation of the liver. The market for hepatitis C treatments is expected to be worth around $15 billion by 2019, garnering significant investor interest, and most firms trying to develop a drug for the infection have seen stock prices skyrocketing over the past one year. Shares of Achillion closed at $6.89 on Monday on the Nasdaq.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions